LEAD PLAINTIFF DEADLINE IS DECEMBER 15, 2025.
If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at info@ktmc.com.
Case Background:
A class action lawsuit was filed on behalf of those who purchased or otherwise acquired MoonLake Immunotherapeutics (“MoonLake”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”).
MoonLake is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17, particularly in dermatology and rheumatology. Its sole drug candidate, sonelokimab (“SLK”), is developed primarily for the treatment of hidradenitis suppurativa (“HS”), a chronic, painful skin disorder characterized by recurrent nodules and abscesses.
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) SLK and bimekizumab-bkzx (“BIMZELX”), another company’s FDA approved drug for HS, share the same molecular targets; (2) SLK’s patented Nanobody structure would not deliver a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK’s Nanobody structure purported increase in tissue penetration would not translate to clinical efficacy; and (4) despite touting its novel structure, Defendants lacked a reasonable basis for their positive statements regarding SLK’s purported superiority to monoclonal antibodies; and (5) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
What is a Lead Plaintiff?
A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.